title: Effects of a new calcium channel blocker, TA 3090, on serum lipoprotein levels in mild to moderate essential hypertension.
abstract: The 25 hypertensive patients received 20 to 40 mg of TA 3090 daily for 12 weeks. Blood pressures declined significantly during treatment, from a mean of 162/98 to 145/88 mmHg. There were no significant changes in levels of total or very low-density lipoprotein cholesterol or triglyceride, in levels of low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, HDL2 cholesterol, HDL3 cholesterol, or in levels of apolipoprotein (apo) B, C-II, C-III, or E. Apo A-I and A-II levels increased significantly from 130 and 29.2 mg/dl before treatment to 152 and 31.4 mg/dl at 12 weeks. Mean serum creatinine levels decreased significantly from 0.92 to 0.80 mg/dl. No other drug-related changes in laboratory test results or side effects were noted. It is concluded that TA 3090 is a safe and effective treatment for mild to moderate hypertension.
authors.affiliation: Fukuoka University Hospital, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: M
authors.initials: M
authors.lastname: Ideishi
authors.forename: K
authors.initials: K
authors.lastname: Saku
authors.forename: K
authors.initials: K
authors.lastname: Arakawa
authors.forename: K
authors.initials: K
authors.lastname: Tominaga
authors.forename: Y
authors.initials: Y
authors.lastname: Saeki
authors.forename: N
authors.initials: N
authors.lastname: Otake
authors.forename: K
authors.initials: K
authors.lastname: Kawasaki
authors.forename: K
authors.initials: K
authors.lastname: Shirai
authors.forename: I
authors.initials: I
authors.lastname: Sumida
mesh_terms: D000328:Adult; D000368:Aged; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D004110:Diltiazem / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013841:Thiazepines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002121:Calcium Channel Blockers; D008074:Lipoproteins; D013841:Thiazepines; C056595:clentiazem; D004110:Diltiazem